- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.10. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 27.10. | Polyrizon Ltd.: Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker | 3 | GlobeNewswire (USA) | ||
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| 07.10. | Polyrizon Ltd. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 05.10. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 05.10. | Polyrizon erweitert Patentschutz für nasale Drug-Delivery-Technologie | 4 | Investing.com Deutsch | ||
| 05.10. | Polyrizon Ltd.: Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform | 221 | GlobeNewswire (Europe) | A new patent application covers Polyrizon's proprietary mucoadhesive platform and its potential applications in nasal drug delivery. Raanana, Israel, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd.... ► Artikel lesen | |
| 28.09. | Polyrizon Ltd. GAAP EPS of -$0.79 | 1 | Seeking Alpha | ||
| 28.09. | Polyrizon Ltd. - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 28.09. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.09. | Polyrizon enrolls first patient in U.S. allergy blocker trial | - | Investing.com | ||
| 22.09. | Polyrizon Ltd.: Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker | 199 | GlobeNewswire (Europe) | First patient marks Polyrizon's transition into a clinical-stage company. The U.S clinical study is designed to evaluate the efficacy, safety and tolerability of the NASARIX (PL-14) Allergy Blocker... ► Artikel lesen | |
| 04.09. | Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement | 3 | GlobeNewswire (USA) | ||
| 04.09. | Polyrizon Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 03.09. | Polyrizon prices $4M registered direct offering | 1 | Seeking Alpha | ||
| 03.09. | Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement | 1 | GlobeNewswire (USA) | ||
| 02.09. | Polyrizon Tumbles on Clinical Studies | 1 | Baystreet.ca | ||
| 02.09. | Polyrizon Ltd.: Polyrizon Completes All Five U.S. Site Contracts for NASARIX First-in-Human Allergy Study | 2 | GlobeNewswire (USA) | ||
| 20.08. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.08. | Polyrizon completes contracting with all five clinical sites | 1 | Investing.com | ||
| 20.08. | Polyrizon Ltd.: Polyrizon Completes Clinical Site Network for NASARIX Study and Advances Toward Patient Enrollment | 1 | GlobeNewswire (USA) |
1 2 3 4 Weiter >>
61 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,205 | -0,14 % | Ihre wichtigsten Termine: Spannende Updates von: Moderna, Krones, Daimler Truck, Under Armour & Brookfield | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: CA29250N1050... ► Artikel lesen | |
| VALNEVA | 2,499 | +0,40 % | Valneva: Britische Zulassung für Ixchiq widerrufen - der Druck auf die Aktie bleibt hoch | ||
| NOVAVAX | 9,710 | +0,31 % | Novavax, Inc.: Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights | Reports total revenue of $68 million for the third quarter of 2026Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 6,480 | +3,35 % | This Palatin Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday | ||
| BIOXXMED | 0,850 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 30.10.2026 | The following instruments on XETRA do have their last trading day on 30.10.2026Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 30.10.2026ISIN NameDE000A41YD32 BIOXXMED AG INH O.N.DE000HLB78G8... ► Artikel lesen | |
| OCUGEN | 0,841 | +1,33 % | Ocugen im Check: OCU400-Lizenz für MENA - der nächste Baustein | ||
| INOVIO PHARMACEUTICALS | 1,050 | -3,76 % | Aktien New York Ausblick: Erholungsversuch vor US-Zwischenwahlen | NEW YORK (dpa-AFX) - Nach den herben Verlusten vom Freitag und vor den am Dienstag anstehenden Zwischenwahlen in den USA dürften die US-Börsen am Montag einen Erholungsversuch starten. Im Anlegerfokus... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 5,010 | -0,99 % | XFRA ET80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 0,618 | +0,98 % | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
Ongoing negotiations with different parties towards securing a partnership or financing for the development... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,960 | -0,37 % | SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales Decline | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,070 | +2,22 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 10-Q, Quarterly Report | ||
| REDHILL BIOPHARMA | 0,428 | 0,00 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| PHIO PHARMACEUTICALS | 0,789 | -1,54 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer) | INTASYL siRNA - Redefining the Treatment Paradigm for Cutaneous Squamous Cell CarcinomaKing of Prussia, Pennsylvania--(Newsfile Corp. - November 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO)... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 6,000 | +0,84 % | Ocular Therapeutix, Inc.: Ocular Therapeutix' Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
POLYRIZON LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 11,520 Euro und damit -0,60 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.